請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59762
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡孟勳(Mong-Hsun Tsai) | |
dc.contributor.author | Yao-Chin Hsieh | en |
dc.contributor.author | 謝耀慶 | zh_TW |
dc.date.accessioned | 2021-06-16T09:36:42Z | - |
dc.date.available | 2022-02-17 | |
dc.date.copyright | 2017-02-17 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-11 | |
dc.identifier.citation | 1. Fitzmaurice, C., et al., The Global Burden of Cancer 2013. JAMA Oncology, 2015. 1(4): p. 505-27.
2. Stewart, B., et al., World cancer report 2014. World Cancer Report, 2015. 3. Zhang, H.-Z., et al., Epidemiologic differences in esophageal cancer between Asian and Western populations. Chinese Journal of Cancer, 2012. 31(6): p. 281. 4. Croghan, G.A. Gastrointestinal oncology: principles and practices. in Mayo Clinic Proceedings. 2002. Gastroenterology. 5. 陳旺全, 食道癌之中醫治療. 中醫藥研究論叢, 2009. 12(1): p. 45-60. 6. Schottenfeld, D., et al., Cancer epidemiology and prevention. 1982: Eastbourne, UK; WB Saunders Co. 7. Zhang, L., et al., Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Scientific Reports, 2015. 5: p. 10798. 8. Natsugoe, S., et al., The role of salvage surgery for recurrence of esophageal squamous cell cancer. European Journal of Surgical Oncology, 2006. 32(5): p. 544-7. 9. Enzinger, P.C., et al., Esophageal cancer. The New England Journal of Medicine, 2003. 349(23): p. 2241-52. 10. Kimura, H., et al., Number of lymph node metastases influences survival in patients with thoracic esophageal carcinoma: therapeutic value of radiation treatment for recurrence. Diseases of the Esophagus, 1999. 12(3): p. 205-8. 11. Baba, M., et al., Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Annals of Surgery, 1994. 219(3): p. 310-6. 12. Sherman, M., Recurrence of hepatocellular carcinoma. The New England Journal of Medicine, 2008. 359(19): p. 2045-7. 13. Ahmad, A., Pathways to breast cancer recurrence. ISRN Oncology, 2013. 2013: p. 290568. 14. Lee, S.H., et al., Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2015. 78(4): p. 341-8. 15. Sinicrope, F.A., et al., DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. The Journal of the National Cancer Institute, 2011. 103(11): p. 863-75. 16. Ribelles, N., et al., Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Research, 2013. 15(5): p. R98. 17. Nakagawa, S., et al., Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. Journal of the American College of Surgeons, 2004. 198(2): p. 205-11. 18. Ma, G., et al., MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell carcinoma. Oncotarget, 2016. 7(15): p. 20209-22. 19. Uchi, Y., et al., CXCL12 expression promotes esophageal squamous cell carcinoma proliferation and worsens the prognosis. BMC Cancer, 2016. 16: p. 514. 20. Tan, H.Z., et al., Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients. BMC Cancer, 2016. 16(560). 21. Jia, Y., et al., Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy. Peer J, 2015. 3: p. e1355. 22. Peng, Y., et al., MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression. PLoS One, 2014. 9(4): p. e94422. 23. Rana, T.M., Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews Molecular Cell Biology, 2007. 8(1): p. 23-36. 24. Valencia-Sanchez, M.A., et al., Control of translation and mRNA degradation by miRNAs and siRNAs. Genes & Development, 2006. 20(5): p. 515-24. 25. He, Z., et al., MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Molecular Cancer, 2016. 15(1): p. 51. 26. Yang, F., et al., MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. Gene, 2016. 11(600): p. 21-28. 27. Yang, H., et al., MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. American Journal of Cancer Research, 2016. 6(11): p. 2690-2699. 28. Osako, Y., et al., Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. International Journal of Oncology, 2016. 49(6): p. 2255-64. 29. Liu, C., et al., miR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1. Molecular and cellular biochemistry, 2015. 398(1-2): p. 115-122. 30. Hong-Yuan, W., et al., miR-338-3p suppresses epithelial-mesenchymal transition and metastasis in human nonsmall cell lung cancer. Indian Journal of Cancer, 2015. 52 Suppl 3: p. E168-71. 31. Ma, X., et al., miR-338-5p modulates B cell biological functions by targeting NF-kappaB1. Chinese Journal of Cellular and Molecular Immunology, 2016. 32(11): p. 1475-1480. 32. Xing, Z., et al., Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell & Bioscience, 2016. 6: p. 53. 33. Zhuang, Y., et al., MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1. American Journal of Translational Research, 2016. 8(7): p. 3197-205. 34. Mahawithitwong, P., et al., Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma. Pancreas, 2013. 42(4): p. 663-9. 35. Ge, Y.S., et al., Kindlin-2: a novel prognostic biomarker for patients with hepatocellular carcinoma. Pathology, Research and Practice, 2015. 211(3): p. 198-202. 36. Wei, X., et al., Kindlin-2 mediates activation of TGF-beta/Smad signaling and renal fibrosis. Journal of the American Society of Nephrology, 2013. 24(9): p. 1387-98. 37. Yang, J.R., et al., Kindlin-2 promotes invasiveness of prostate cancer cells via NF-kappaB-dependent upregulation of matrix metalloproteinases. Gene, 2016. 576(1 Pt 3): p. 571-6. 38. Fukuda, K., et al., Molecular basis of kindlin-2 binding to integrin-linked kinase pseudokinase for regulating cell adhesion. The Journal of Biological Chemistry, 2014. 289(41): p. 28363-75. 39. Cao, H.H., et al., A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget, 2015. 6(7): p. 5435-48. 40. Besse, A., et al., MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response. Tumor Biology, 2015. 37(6): p. 7719-27. 41. Nakata, W., et al., Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma. Oncotarget, 2015. 6(25): p. 21645-54. 42. Zhao, Y., et al., MicroRNA-27a-3p Inhibits Melanogenesis in Mouse Skin Melanocytes by Targeting Wnt3a. International Journal of Molecular Sciences, 2015. 16(5): p. 10921-33. 43. Zhao, N., et al., miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC. Scientific Reports, 2016. 6: p. 23091. 44. Yao, S., et al., Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1. Oncotarget, 2016. 7(27): p. 42566-42578. 45. Yu, Y., et al., Kindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family. International Journal of Cancer, 2013. 133(6): p. 1368-79. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59762 | - |
dc.description.abstract | MicroRNAs (miRNAs)是一段長度約22-24個鹼基對的小分子核糖核酸,會藉由與mRNA的3端不轉譯區 (3’untranslation region, 3’UTR)進行結合去抑制基因的轉譯達到調控基因的目的。近年來,許多文獻證實miRNA與腫瘤的增生、轉移、藥物敏感度以及細胞癌化程度等有高度相關性。另外,也有研究發現miRNA表現量會與食道癌病患的存活時間或癌症復發等預後情形相關,所以miRNA在腫瘤發展與預後扮演相當重要的角色。我們實驗室先前選取4位復發與4位沒復發的食道癌病患檢體並利用次世代定序平台 (next generation sequencing, NGS)發現miR-338-5p在沒復發的檢體中具有較高的表現量,因此推測miR-338-5p可能與腫瘤復發有相關。在過往文獻中提到miR-338-5p對於其他腫瘤如腦瘤、肝癌等癌細胞的轉移以及放射線敏感度有相關性,但是在食道鱗狀細胞癌中,miR-338-5p的調控機制與影響的相關研究相當少。因此本研究目的,旨在透過細胞實驗探討miR-338-5p在食道鱗狀癌細胞中,與復發相關的腫瘤特性如遷移、增生以及對化療藥物的敏感度等的影響。研究結果發現,我們在食道癌細胞株CE81T/VGH中大量轉染miR-338-5p後透過穿膜試驗 (transwell assay)、MTT assay與細胞群落形成試驗(colony formation assay)發現細胞的遷移、增生速度與存活率都顯著下降。接著透過miRSystem與Ingenuity Pathways Analysis等軟體的預測,發現FERMT2是miR-338-5p可能的調控基因之一,並透過luciferase reporter assay確認。我們更進一步使用FERMT2 shRNA抑制FERMT2表現,並且透過穿膜試驗、MTT試驗與細胞群落形成試驗發現遷移性、增生速度與存活率在降低FERMT2表現量的食道癌細胞中有顯著下降。此外,我們也使用食道癌常用化療藥物cisplatin處理大量轉染miR-338-5p或抑制FERMT2的食道癌細胞,發現不論大量轉染miR-338-5p或抑制FERMT2的食道癌細胞處理cisplatin後存活細胞數都有下降,顯示轉染miR-338-5p或抑制FERMT2都會提高食道癌細胞對化療藥物的敏感度。最後我們使用來自線上資料庫National Center for Biotechnology Information (NCBI)的資料,分析FERMT2的表現程度對食道癌病患存活率的影響,結果顯示FERMT2低表現的食道癌病患有較長的存活時間。總結研究結果,miR-338-5p可以透過抑制FERMT2的表現進而降低食道癌細胞的遷移、增生速度和存活率與增加對化療藥物的敏感度,同時也可利用miR-338-5p的表達程度做為食道癌預後的生物指標。 | zh_TW |
dc.description.abstract | MicroRNAs (miRNAs) are endogenous non-coding RNAs of 22-24 nucleotides in length that regulate gene expression by complementary binding to the 3’ untranslated regions (3’UTR) of specific mRNA targets. In recent years, accumulating evidences suggested that dysregulated miRNAs can function either as tumor suppressor or oncogenes to affect progression, proliferation, metastasis and drug sensitivity of tumor cells. In addition, many studies mentioned that miRNAs were associated with patients’ prognosis, overall survival and recurrence and may play important roles in tumor progression and prognosis. Our previous study showed that the miR-338-5p expression level was higher in the non-recurrence esophageal squamous cell carcinoma (ESCC) patient samples than that in the recurrence ESCC patient samples by next generation sequencing (NGS) analysis. According to this result, miR-338-5p was considered a miRNA that may relate to ESCC patients’ recurrence. Therefore, the aim of this study is to study the possible roles of miR-338-5p and its underlying mechanisms in ESCC cells. We first transfected miR-338-5p mimic into CE81T/VGH cells, which is an ESCC cell line with higher migration, proliferation and survival ability than other ESCC cell lines. The results showed that the cell migration, proliferation and survival were significantly reduced in the cells with mimic-miR-338-5p using transwell assay, MTT assay and colony formation assay. In order to better understand regulatory mechanisms of miR-338-5p in ESCC cells, miRSystem and Ingenuity Pathways Analysis were used to predict the target genes of miR-338-5p. FERMT2 was identified and validated as the target genes of miR-338-5p using luciferase reporter assay. Furthermore, the results showed that the cell migration, proliferation and survival were significantly reduced in the cells with lower FERMT2 expression using transwell assay, MTT assay and colony formation assay in ESCC cell line. Next, we detected the cisplatin induced cytotoxicity in the CE81T/VGH cells and the results demonstrated that the cells with miR-338-5p overexpression or reduced FERMT2 expression could increase cisplatin induced cytotoxicity in the CE81T/VGH cells. Moreover, we analyzed the relationships between FERMT2 expression levels and the survival time of ESCC patients, and the result indicated that FERMT2 could be a good biomarker to predict the survival outcome of esophageal cancer patients. In summary, our study suggested that miR-338-5p might reduce cell proliferation, migration, survival, and to enhance the cisplatin sensitivity in the ESCC cells through FERMT2 regulation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:36:42Z (GMT). No. of bitstreams: 1 ntu-106-R03642001-1.pdf: 2238046 bytes, checksum: 61d7b1f89ba09193b2b3c7a5f9399649 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝......................................................I
中文摘要.................................................II ABSTRACT................................................IV 目錄.....................................................VI 圖目錄..................................................VII 表目錄.................................................VIII 第一章 序論與文獻回顧......................................1 第一節 食道癌介紹..........................................1 (一)食道癌介紹.............................................1 (二)食道癌的治療...........................................1 (三)食道癌預後與復發.......................................2 第二節 小分子核糖核酸......................................4 (一)小分子核糖核酸.........................................4 (二)miRNA與腫瘤惡性功能相關研究............................5 第三節 miR-338介紹........................................6 (一)miR-338-3p介紹........................................6 (二)miR-338-5p介紹........................................6 第四節 FERMT2介紹.........................................6 (一)FERMT2介紹............................................6 第二章 研究目的與架構......................................8 第三章 材料與方法..........................................9 第四章 研究結果...........................................18 第一節 利用NGS分析食道癌病患樣本中miRNA的表現量.............18 第二節 利用食道癌細胞株探討miR-338-5p對癌細胞的影響.........19 第三節 利用miRSystem以及IPA預測miR-338-5p的標的基因........20 第四節 冷光試驗驗證FERMT2是 miR-338-5p的標的基因...........20 第五節 利用細胞實驗探討FERMT2對食道癌細胞株的影響...........21 第六節 miR-338-5p與FERMT2對化療藥物cisplatin的藥物敏感度的影響.......................................................22 第七節 探討FERMT2對食道癌病患的預後存活率...................23 第五章 討論與結論.........................................24 第六章 未來方向...........................................27 圖與表...................................................28 參考文獻.................................................51 | |
dc.language.iso | zh-TW | |
dc.title | miR-338-5p藉由調控FERMT2進而抑制食道鱗狀癌細胞的增生、遷移與存活率,並增強對化療藥物的敏感度 | zh_TW |
dc.title | miR-338-5p regulates FERMT2 to modulate cell proliferation, migration, survival, and cisplatin sensitivity in esophageal squamous cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 莊曜宇(Eric Y. Chuang),賴亮全(Liang-Chuan Lai),侯明模 | |
dc.subject.keyword | miR-338-5p,FERMT2,食道癌,細胞遷移,增生,存活率,Cisplatin,復發, | zh_TW |
dc.subject.keyword | miR-338-5p,FERMT2,ESCC,Migration,Proliferation,Survival,Cisplatin,Recurrence, | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU201700511 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-02-12 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 生物科技研究所 | zh_TW |
顯示於系所單位: | 生物科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。